- Sulfonylurea compound synthesis method
-
The invention discloses a sulfonylurea compound synthesis method, which comprises: respectively dissolving p-toluenesulfonyl isocyanate and an amino compound in an organic solvent to obtain a p-toluenesulfonyl isocyanate organic solution and an amino compound organic solution; under the protection of nitrogen and/or inert gas, dropwise adding the amino compound organic solution into the p-toluenesulfonyl isocyanate organic solution for reaction; and after the reaction is finished, carrying out rotary evaporation to remove the solvent, and removing impurities to obtain the sulfonylurea compound. According to the synthesis method, the sulfonylurea compound can be prepared at the room temperature through specific raw material selection, energy consumption is reduced, meanwhile, the synthesis method is easy to operate, the synthesized product is easy to separate, and the purity of the product is high.
- -
-
Paragraph 0027; 0032-0055
(2021/11/26)
-
- Combinations comprising dipeptidylpeptidase-iv inhibitor
-
The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase-IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.
- -
-
-